Basilea & Roche to jointly study novel treatment for urothelial cancer
Category: #health  By Nikita Chaurasia  Date: 2019-01-24
  • share
  • Twitter
  • Facebook
  • LinkedIn

Basilea & Roche to jointly study novel treatment for urothelial cancer

The planned study would assess the efficacy, tolerability, and safety of the derazantinib-atezolizumab combination in patients with confirmed FGFR genomic aberrations and advanced urothelial cancer.

Basilea Pharmaceutica Limited, a commercial stage biopharmaceutical company, has reportedly announced a partnership with Roche to discover a combination of Roches PD-L1-blocking immune-checkpoint inhibitor atezolizumab (Tecentriq®) and Basileas derazantinib for people suffering from urothelial cancer.

Chief Medical Officer of Basilea Pharmaceutica Ltd, Dr. Marc Engelhardt was reportedly quoted saying that the firm is delighted to collaborate with Roche as the looks forward to explore a unique targeted treatment approach which addresses the high medical need of patients suffering from urothelical cancer. The combination of atezolizumab and derazantinib is based on a sound scientific rationale. Moreover, derazantinib has the capacity to improve the response to atezolizumab's immune-checkpoint inhibition.

For the uninitiated, derazantinib is called a panFGFR kinase inhibitor as it is known to be an investigational orally administered small molecule inhibitor of the FGFR family of kinases with strong activity against FGFR1, 2, and 3.

According to a press release by Basilea Pharmaceutica, the planned study would assess the efficacy, tolerability, and safety of the derazantinib-atezolizumab combination in patients with confirmed FGFR genomic aberrations and advanced urothelial cancer. Roche would provide clinical supply of atezolizumab and Basilea will be sponsoring the study, cite reliable sources.

Reportedly, the combination of inhibiting FGFR while, at the same time, improving T cell-mediated antitumor effects via CSF1R inhibition is potentially a promising new treatment approach in patients suffering from urothelial cancer.

For the record, urothelial cancer is the sixth most common cancer in the United States. These cancers begin in the urothelial cells that line the inside of the bladder. About 80,000 new cases of bladder cancer registered in the nation in the year 2017.

Sources familiar with the development claim that Basilea anticipates to begin a biomarker-driven multi-cohort phase 1/2 study by mid-2019.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

Japan’s SoftBank amid plans to invest in venture capital funds
Japan’s SoftBank amid plans to invest in venture capital funds
By Nikita Chaurasia

The conglomerate plans to mark its presence in Latin America by investing in venture capital funds, with a strategy to deploy nearly $500 million in five to 10 funds. SoftBank Group Corp., a multinational conglomerate based out of Tokyo, reportedly ...

TG Manufacturing acquires contract manufacturing firm TurnKey
TG Manufacturing acquires contract manufacturing firm TurnKey
By Nikita Chaurasia

TurnKey presently supplies a varied group of consumers in the industrial laboratory, defense and gaming industries among others. Using TGM’s advanced manufacturing technology, quality systems and global network and combining them with TurnKe...

Oxurion concludes enrollment of patients for THR-687 Phase 1 trial
Oxurion concludes enrollment of patients for THR-687 Phase 1 trial
By Nikita Chaurasia

12 patients with DME have enrolled into the study.   The results for the Phase 1 trial will be out by the end of 2019. Oxurion NV, a biopharmaceutical firm involved in the development of innovative treatments to preserve vision of diabetic...